Prevention of bone loss in kidney graft recipients.
University Medical Centre, Department of Nephrology, Ljubljana, Slovenia. Damjan.Kovac@guest.arnes.si
D
D
Kovac
J
J
Lindic
A
A
Kandus
A F
AF
Bren
D000328:Adult; D019386:Alendronate / Q000627:therapeutic use; D015519:Bone Density; D001862:Bone Resorption / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use; D002119:Calcium Carbonate / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016030:Kidney Transplantation / Q000009:adverse effects* / Q000502:physiology; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use; D015663:Osteoporosis, Postmenopausal / Q000209:etiology / Q000517:prevention & control; D014807:Vitamin D / Q000627:therapeutic use
D002120:Calcium Channel Agonists; D005938:Glucocorticoids; D014807:Vitamin D; D002117:Calcitriol; D002119:Calcium Carbonate; D002118:Calcium; D019386:Alendronate; D008775:Methylprednisolone